IGC PharmaIGC +1.48%29 PS Ratio is 21.15 as of Jun. 30, 2026, which is 13% above its 10-year median of 18.80. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 935 Biotechnology companies, IGC Pharma ranks worse than 65.56% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, IGC Pharma's share price is $0.275.
IGC Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, IGC Pharma's PS Ratio for today is 21.15.
The historical rank and industry rank for IGC Pharma's PS Ratio or its related term are showing as below:
IGC'
s PS Ratio Range Over the Past 10 Years
Min: 1.26 Med: 18.8 Max: 188
Current: 21.15
During the past 13 years, IGC Pharma's highest PS Ratio was 188.00. The lowest was 1.26. And the median was 18.80.
IGC's PS Ratio is ranked worse than 65.56% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs IGC: 21.15
IGC Pharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of IGC Pharma was -18.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 28.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -20.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -27.80% per year.
During the past 13 years, IGC Pharma's highest 3-Year average Revenue per Share Growth Rate was 275.60% per year. The lowest was -65.50% per year. And the median was -32.90% per year.
Back to Basics: PS Ratio
IGC Pharma (AMEX:IGC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
IGC Pharma PS Ratio Related Terms
IGC Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for IGC Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where IGC Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
IGC Pharma's Share Price of today is $0.275. IGC Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
IGC Pharma (IGC) has a PS Ratio of 21.15 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on IGC Pharma and its competitors. This is 13% above median its historical median of 18.80. Over the past decade, IGC Pharma's PS Ratio has ranged from 1.26 to 188.00. According to the industry distribution chart, IGC Pharma ranks #613 out of 935 companies in the Biotechnology industry, placing it in the top 65.6%.
Is IGC Pharma's PS Ratio too high?
IGC Pharma's current PS Ratio of 21.15 is 13% above median its 10-year median of 18.80. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 188.00. The Biotechnology industry median PS Ratio is 9.37. IGC Pharma's value of 21.15 is 125.7% above this industry median. Based on the distribution chart, IGC Pharma ranks #613 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's PS Ratio compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #613 out of 935 companies for PS Ratio. This places IGC Pharma in the lower half of its industry. The industry median PS Ratio is 9.37. IGC Pharma's value of 21.15 is 125.7% above this benchmark. Historically, IGC Pharma's own PS Ratio has ranged from 1.26 to 188.00 over the past decade. While the company's 10-year median is 18.80 vs. the industry median of 9.37, IGC Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current PS Ratio of 21.15 is 125.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current PS Ratio is 21.15, which is 13% above median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.28 — trading 14.6% above its estimated fair value. The current PS Ratio is 21.15, which is 13% above median its 10-year median of 18.80 and 125.7% above the Biotechnology industry median of 9.37. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For IGC Pharma (IGC), the current PS Ratio is 21.15 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.28 is trading 14.6% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
PS Ratio: 21.15 (13% above median its 10-year median of 18.80)
GF Value™: $0.24 vs. price of $0.28 (14.6% above fair value)
Industry Position: 125.7% above the Biotechnology median (#613 of 935)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
